MHS » Topics » Financing Facilities

This excerpt taken from the MHS 10-K filed Feb 24, 2009.
Financing Facilities
 
Five-Year Credit Facilities
 
We have a senior unsecured credit facility consisting of a $1 billion, 5-year senior unsecured term loan and a $2 billion, 5-year senior unsecured revolving credit facility. The term loan matures on April 30, 2012, at which time the entire facility is required to be repaid. If there are pre-payments on the term loan prior to the maturity date, that portion of the loan would be extinguished. At our current debt ratings, the credit facilities bear interest at London Interbank Offered Rate (“LIBOR”) plus a 0.45 percent margin, with a 10 basis point commitment fee due on the unused portion of the revolving credit facility.
 
During 2008, our net borrowings under the revolving credit facility decreased by approximately $400 million, consisting of repayments of $2.2 billion and draw-downs of $1.8 billion. As a result of this activity, the revolving credit facility’s outstanding balance decreased from $1.4 billion at fiscal year-end 2007 to $1.0 billion as of December 27, 2008. As of December 27, 2008, we had $987 million available for borrowing under our revolving credit facility, after giving effect to $13 million in issued letters of credit, an increase from the $587 million available for borrowing as of December 29, 2007, after giving effect to $13 million in issued letters of credit. The revolving credit facility is available through April 30, 2012.
 
On October 31, 2007, we drew down $1 billion under the revolving credit facility in order to partially fund the acquisition of PolyMedica. We also drew down an additional $400 million under the revolving credit facility in the fourth quarter of 2007, primarily to pay down PolyMedica’s outstanding debt balances and to acquire Critical Care. For more information on the acquisitions of PolyMedica and Critical Care, see Note 3, “Acquisitions of Businesses,” to the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.
 
2007 Refinancing
 
In connection with a refinancing in April 2007, our pre-existing senior unsecured credit facilities were extinguished and our indebtedness outstanding pursuant to such facilities was paid in full. The pre-existing facilities consisted of a $750 million senior unsecured term loan under which we had quarterly installments, and a $750 million senior unsecured revolving credit facility. The pre-existing credit facilities incurred interest at LIBOR plus a 0.5 percent margin, with a 12.5 basis point commitment fee due on the unused revolving credit facility.
 
Accounts Receivable Financing Facility
 
Through a wholly-owned subsidiary, we have a $600 million, 364-day renewable accounts receivable financing facility that is collateralized by our pharmaceutical manufacturer rebate accounts receivable. At December 27, 2008, there was $600 million outstanding with no additional amounts available for borrowing under the facility. We pay interest on amounts borrowed under the agreement based on the funding rates of the bank-related commercial paper programs that provide the financing, plus an applicable margin determined by our credit rating. The weighted average annual interest rate on amounts borrowed under the facility as of December 27, 2008 and December 29, 2007 was 3.10% and 5.49%, respectively. This facility is renewable annually in July at the option of both Medco and the banks. If our accounts receivable financing facility is not renewed, we have adequate capacity under our revolving credit facility.
 
Interest Rates
 
The weighted average annual interest rate on our indebtedness was approximately 5.1% for 2008 and 6.3% for both 2007 and 2006 and reflects variability in floating interest rates on the senior unsecured credit facilities, swap agreements and the accounts receivable financing facility. Several factors could change the weighted average annual interest rate, including but not limited to a change in our debt ratings, reference rates used under our bank credit facility, swap agreements and the mix of our debt, including the effect of our March 2008 issuance of senior notes.


57


Table of Contents

Swap Agreements
 
On December 12, 2007, we entered into forward-starting interest rate swap agreements in contemplation of the issuance of long-term fixed-rate financing. We entered into these cash flow hedges to manage our exposure to changes in benchmark interest rates and to mitigate the impact of fluctuations in the interest rates prior to the issuance of the long-term financing. The cash flow hedges entered into were for a notional amount of $500 million on the then-current 10-year treasury interest rate, and for a notional amount of $250 million on the then-current 30-year treasury interest rate, both with a settlement date of March 31, 2008. At the time of purchase, the cash flow hedges were anticipated to be effective in offsetting the changes in the expected future interest rate payments on the proposed debt offering attributable to fluctuations in the treasury benchmark interest rate. As of December 29, 2007, we included in accumulated other comprehensive income an unamortized swap loss of $7.9 million ($4.8 million, net of tax).
 
In connection with the issuance of the 5-year senior notes and 10-year senior notes described above, a portion of the $250 million notional amount 30-year treasury interest rate cash flow hedge was deemed an ineffective hedge. The cash flow hedges were settled on March 17, 2008 for $45.4 million and included the ineffective portion that was recorded as an increase of $9.8 million to interest (income) and other (income) expense, net, for the year ended December 27, 2008. The effective portion was recorded in accumulated other comprehensive income and is reclassified to interest expense over the ten-year period in which we hedged our exposure to variability in future cash flows. The unamortized effective portion reflected in accumulated other comprehensive income as of December 27, 2008 was $20.0, net of tax.
 
In 2004, we entered into five interest rate swap agreements on $200 million of the $500 million in 7.25% senior notes. We entered into these swap agreements as an effective hedge to (i) convert a portion of the senior note fixed rate debt into floating rate debt; (ii) maintain a capital structure containing appropriate amounts of fixed and floating rate debt; and (iii) lower the interest expense on these notes in the near term. We do not expect our cash flows to be affected to any significant degree by a sudden change in market interest rates.
 
Covenants
 
All of the senior notes discussed above are subject to customary affirmative and negative covenants, including limitations on sale/leaseback transactions; limitations on liens; limitations on mergers and similar transactions; and a covenant with respect to certain change of control triggering events. The 6.125% senior notes and the 7.125% senior notes are also subject to an interest rate adjustment in the event of a downgrade in the ratings to below investment grade. In addition, the senior unsecured credit facilities and the accounts receivable financing facility are subject to covenants, including, among other items, maximum leverage ratios. We were in compliance with all covenants at December 27, 2008 and December 29, 2007.
 
Debt Ratings
 
Medco’s debt ratings, all of which represent investment grade, are as follows as of the filing date of this Annual Report on Form 10-K: Moody’s Investors Service, Baa3; Standard & Poor’s, BBB; Fitch Ratings, BBB.
 
This excerpt taken from the MHS 10-Q filed Nov 1, 2007.

Financing Facilities

Senior Bank Credit Facility and Refinancing. On April 30, 2007, we entered into a senior unsecured credit agreement which, in addition to replacing our existing senior unsecured credit facility, is available to fund our share repurchase program, general corporate activities, working capital requirements, capital expenditures and acquisitions. In connection with the refinancing, our pre-existing senior unsecured credit facility was extinguished and our indebtedness outstanding pursuant to such facility was paid in full. The current facility consists of a $1 billion, 5-year senior unsecured term loan and a $2 billion, 5-year senior unsecured revolving credit facility. The pre-existing facility consisted of a $750 million senior unsecured term loan and a $750 million senior unsecured revolving credit facility. The current term loan matures on April 30, 2012, at which time the outstanding balance is required to be repaid, compared with the pre-existing credit facility, under which we had quarterly installment payments. At our current debt ratings, the current credit facility bears interest at London Interbank Offered Rate (“LIBOR”) plus a 0.45 percent margin, with a 10 basis point commitment fee due on the unused revolving credit facility. The pre-existing credit facility incurred interest at LIBOR plus a 0.5% margin, with a 12.5 basis point commitment fee due on the unused revolving credit facility.

As of September 29, 2007, we had $1 billion outstanding under the term loan facility. In addition, we had no amounts outstanding and had $1.987 billion available for borrowing, after giving effect to $13 million in issued letters of credit, under the revolving credit facility.

On October 31, 2007, we drew down $1 billion under the revolving credit facility in order to partially fund the acquisition of PolyMedica Corporation. For more information, see Note 11, “Subsequent Events—PolyMedica Acquisition,” to the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

Accounts Receivable Financing Facility. Through a wholly-owned subsidiary, we have a $600 million, 364-day renewable accounts receivable financing facility that is collateralized by our pharmaceutical manufacturer rebate accounts receivable. At September 29, 2007, there was $600 million outstanding with no additional amounts available for borrowing under the facility. We pay interest on amounts borrowed under the agreement based on the funding rates of the bank-related commercial paper programs that provide the financing, plus an applicable margin determined by our credit rating. During the first nine months of 2007, we drew down $275 million under the facility.

Interest Rates and Covenants. The weighted average annual interest rate on our indebtedness was approximately 6.4% and 6.5% for the third quarter and nine months of 2007, respectively, and 6.5% and 6.2% for the third quarter and nine months of 2006, respectively. Several factors could change the weighted average annual interest rate, including but not limited to a change in reference rates used under our bank credit facility and swap agreements.

Our senior unsecured credit facility, senior notes, and accounts receivable financing facility contain covenants, including, among other items, maximum leverage ratios. We were in compliance with all financial covenants at September 29, 2007. As a result of the aforementioned refinancing, our financial covenants are slightly less restrictive.

Debt Ratings. Medco’s debt ratings, all of which represent investment grade, reflect the following as of the filing date of this Quarterly Report on Form 10-Q: Moody’s Investors Service, Baa3; Fitch Ratings, BBB; Standard & Poor’s, BBB. These ratings reflect our refinancing and acquisition of PolyMedica.

 

28


Table of Contents

Looking Forward. We believe that our operating cash flows will continue to be positive and adequate to fund our ongoing operations, our debt service requirements and capital investments for the next twelve months and in the foreseeable future. However, we may incur additional indebtedness by drawing down additional amounts under our senior unsecured revolving credit facility or by obtaining financing through other sources, in order to, for example, fund strategic investments.

It is anticipated that our 2007 base capital expenditures, for items such as capitalized software development for strategic initiatives and infrastructure enhancements, will be approximately $150 million. We have no immediate plans for dividend payments.

This excerpt taken from the MHS 10-Q filed Jul 27, 2007.

Financing Facilities

Senior Bank Credit Facility and Refinancing. On April 30, 2007, we entered into a new senior unsecured credit agreement which, in addition to replacing our previously existing senior unsecured bank credit facility, is available to support our recently expanded share repurchase program, general corporate activities, working capital requirements and capital expenditures. In connection with the new credit facility, our previously existing senior bank credit facility was terminated and our existing indebtedness outstanding pursuant to such facility was paid in full. The new facility is comprised of a $1 billion, 5-year senior unsecured term loan and a $2 billion, 5-year senior unsecured revolving credit facility, compared with the previously existing $750 million senior unsecured term loan facility and the $750 million senior unsecured revolving credit facility. The new term loan matures on April 30, 2012, at which time the outstanding balance is required to be repaid, compared with the previously existing credit facility, under which we had quarterly installment payments. At current debt ratings, the new credit facility bears interest at London Interbank Offered Rate (“LIBOR”) plus a 0.45 percent margin, with a 10 basis point commitment fee due on the unused revolving credit facility. The previously existing credit facility incurred interest at the LIBOR plus a 0.5% margin.

As of June 30, 2007, we had $1 billion outstanding under the term loan facility. In addition, we had no amounts outstanding and had $1.987 billion available for borrowing, exclusive of $13 million in issued letters of credit, under the revolving credit facility.

 

25


Table of Contents

Accounts Receivable Financing Facility. Through a wholly-owned subsidiary, we have a $600 million, 364-day renewable accounts receivable financing facility that is collateralized by our pharmaceutical manufacturer rebate accounts receivable. At June 30, 2007, there was $600 million outstanding with no additional amounts available for borrowing under the facility. We pay interest on amounts borrowed under the agreement based on the funding rates of the bank-related commercial paper programs that provide the financing, plus an applicable margin determined by our credit rating. During the first six months of 2007, we drew down $275 million under the facility.

Interest Rates and Covenants. The estimated weighted average annual interest rate on our indebtedness was approximately 6.4% and 6.6% for the second quarter and six months of 2007, respectively, and 6.3% and 6.1% for the second quarter and six months of 2006, respectively. Several factors could change the weighted average annual interest rate, including but not limited to a change in reference rates used under our bank credit facility and swap agreements.

Our senior unsecured credit facility, senior notes, and accounts receivable financing facility contain covenants, including, among other items, maximum leverage ratios. We were in compliance with all financial covenants at June 30, 2007. As a result of the aforementioned refinancing, our financial covenants are slightly less restrictive.

Debt Ratings. Medco’s debt ratings, all of which represent investment grade, reflect the following as of the filing date of this Quarterly Report on Form 10-Q: Moody’s Investors Service, Baa3 (stable outlook); Fitch Ratings, BBB (stable outlook); Standard & Poor’s, BBB (stable outlook). These ratings reflect the recent refinancing.

This excerpt taken from the MHS 10-Q filed May 2, 2007.

Financing Facilities

Senior Bank Credit Facility. At March 31, 2007, we had a $1.5 billion senior unsecured credit facility, composed of a $750 million term loan and a $750 million revolving credit facility. There was $437.5 million outstanding under our term loan facility as of March 31, 2007. We had no amounts outstanding under our revolving credit facility as of March 31, 2007. Prior to its termination, such credit facility incurred interest at the London Interbank Offered Rate (“LIBOR”) plus a 0.5% margin. At March 31, 2007, we had $737 million available for borrowing under the revolving credit facility, exclusive of $13 million in issued letters of credit. On April 30, 2007, such senior bank credit facility was terminated and our existing indebtedness outstanding pursuant to such facility was satisfied in full in connection with the new credit facility described below.

Accounts Receivable Financing Facility. Through a wholly-owned subsidiary, we have a $600 million, 364-day renewable accounts receivable financing facility that is collateralized by our pharmaceutical manufacturer rebate accounts receivable. At March 31, 2007, there was $600 million outstanding and no amounts available for borrowing under the facility. We pay interest on amounts borrowed under the agreement based on the funding rates of the bank-related commercial paper programs that provide the financing, plus an applicable margin determined by our credit rating. During the first quarter of 2007, we drew down $275 million under the facility.

Subsequent Refinancing. On April 30, 2007, we completed a new bank financing which, in addition to replacing our existing senior unsecured bank credit facility, is available to support our recently expanded share repurchase program, general corporate activities, working capital requirements and capital expenditures. A new $1 billion senior unsecured term loan and a $2 billion senior unsecured revolving credit facility replaced the previously existing $750 million senior unsecured term loan facility, of which $437.5 million was outstanding as of March 31, 2007, and the $750 million senior unsecured revolving credit facility. At current debt ratings, the new credit facility will bear interest at LIBOR plus a 0.45 percent margin, with a 10 basis point commitment fee due on the unused revolving credit facility. As of April 30, 2007, we had $1.987 billion available for borrowing under the revolving credit facility, exclusive of $13 million in issued letters of credit. Due to the debt refinancing, net interest expense is expected to increase by approximately $65 million over 2006 levels throughout the remainder of 2007.

Interest Rates and Covenants. The estimated weighted average annual interest rate on our indebtedness was approximately 6.9% and 5.9% for the quarters ended March 31, 2007 and April 1, 2006, respectively. Several factors

 

25


Table of Contents

could change the weighted average annual interest rate, including but not limited to a change in reference rates used under our bank credit facility and swap agreements.

Our senior unsecured credit facility, senior notes, and accounts receivable financing facility contain covenants, including, among other items, minimum interest coverage and maximum leverage ratios. We were in compliance with all financial covenants at March 31, 2007. Subsequent to the aforementioned refinancing, our financial covenants are somewhat less restrictive and exclude a minimum interest coverage ratio.

Debt Ratings. Medco’s debt ratings, all of which represent investment grade, reflect the following as of May 1, 2007: Moody’s Investors Service, Baa3 (stable outlook); Fitch Ratings, BBB (stable outlook); Standard & Poor’s, BBB (stable outlook). These ratings reflect the subsequent refinancing.

This excerpt taken from the MHS 10-K filed Feb 22, 2007.

Financing Facilities

Senior Bank Credit Facilities. We have a $1.5 billion senior unsecured credit facility, comprised of a $750 million term loan and a $750 million revolving credit facility. There was $456 million outstanding under our term loan facility as of December 30, 2006. We had no amounts outstanding under our revolving credit facility as of December 30, 2006. The credit facilities bear interest at the London Interbank Offered Rate (“LIBOR”) plus a 0.5% margin. In order to provide additional financial flexibility, effective November 17, 2006, our revolving credit facility was increased from $500 million to $750 million. At December 30, 2006, we had $737 million available for borrowing under the revolving credit facility, exclusive of $13 million in issued letters of credit.

Accounts Receivable Financing Facility. Through a wholly-owned subsidiary, as of December 30, 2006, we have a $600 million, 364-day renewable accounts receivable financing facility that is collateralized by our pharmaceutical manufacturer rebate accounts receivable. Effective July 31, 2006, the accounts receivable financing facility was increased from $500 million to $600 million. At December 30, 2006, there was $325 million outstanding and $275 million available for borrowing under the facility. We pay interest on amounts borrowed under the agreement based on the funding rates of the bank-related commercial paper programs that provide the financing, plus an applicable margin determined by our credit rating. The weighted average annual interest rate on amounts borrowed under the facility as of December 30, 2006 was 5.51%.

 

43


Table of Contents
This excerpt taken from the MHS 10-Q filed Nov 3, 2006.

Financing Facilities

Senior Bank Credit Facilities. We have a $1.25 billion senior unsecured credit facility, comprised of a $750 million term loan and a $500 million revolving credit facility. There was $475 million outstanding under our term loan facility as of September 30, 2006. We had no amounts outstanding under our revolving credit facility as of September 30, 2006. The credit facilities bear interest at the London Interbank Offered Rate (“LIBOR”) plus a 0.5% margin.

Accounts Receivable Financing Facility. Through a wholly-owned subsidiary, as of September 30, 2006, we have a $600 million, 364-day renewable accounts receivable financing facility that is collateralized by our pharmaceutical manufacturer rebate accounts receivable. There was $450 million outstanding under this accounts receivable financing facility as of September 30, 2006. We pay interest on amounts borrowed under the agreement based on the funding rates of the bank-related commercial paper programs that provide the financing, plus an applicable margin determined by our credit rating.

Effective July 31, 2006, the accounts receivable financing facility was increased from $500 million to $600 million. During the third quarter of 2006, we drew down and repaid $150 million under the facility.

Interest Rates and Covenants

The estimated weighted average annual interest rate on our indebtedness was approximately 6.5% and 6.2% for the third quarter and nine months of 2006, respectively, and 5.6% and 5.8% for the third quarter and nine months of 2005, respectively. Several factors could change the weighted average annual interest rate, including but not limited to a change in reference rates used under our credit facilities and swap agreements.

Our senior unsecured credit facility, senior notes and accounts receivable financing facility contain covenants, including, among other items, minimum interest coverage, maximum leverage ratios, as well as restrictions on dividends, share repurchases, and asset sales and liens. We were in compliance with all financial covenants at September 30, 2006.

This excerpt taken from the MHS 10-Q filed Aug 4, 2006.

Financing Facilities

Senior Bank Credit Facilities. We have a $1.25 billion senior unsecured credit facility, comprised of a $750 million term loan and a $500 million revolving credit facility. There was $493.8 million under our term loan outstanding as of July 1, 2006. We had no amounts outstanding under our revolving credit facility as of July 1, 2006. The credit facilities bear interest at the London Interbank Offered Rate (“LIBOR”) plus a 0.625% margin.

Accounts Receivable Financing Facility. Through a wholly-owned subsidiary, as of July 1, 2006, we had a $500 million, 364-day renewable accounts receivable financing facility that is collateralized by our pharmaceutical manufacturer rebate accounts receivable. There was $450 million outstanding under this accounts receivable financing facility as of July 1, 2006. We pay interest on amounts borrowed under the agreement based on the funding rates of the bank-related commercial paper programs that provide the financing, plus an applicable margin determined by our credit rating.

Subsequent to the quarter ended July 1, 2006 and effective July 31, 2006, the accounts receivable financing facility was increased to $600 million, and on August 1, 2006, we drew down an additional $150 million under the facility, bringing the total amount outstanding under the facility to $600 million.

This excerpt taken from the MHS 10-Q filed May 5, 2006.

Financing Facilities

Senior Bank Credit Facilities. We have a $1.25 billion senior unsecured credit facility, comprised of a $750 million term loan and a $500 million revolving credit facility. There was $512.5 million under our term loan outstanding as of April 1, 2006. The credit facilities bear interest at the LIBOR plus a 0.625% margin.

Accounts Receivable Financing Facility. We, through a wholly-owned subsidiary, have a $500 million, 364-day renewable accounts receivable financing facility that is collateralized by our pharmaceutical manufacturer rebate accounts receivable. There was $450 million under our accounts receivable financing outstanding as of April 1, 2006. We pay interest on amounts borrowed under the agreement based on the funding rates of the bank-related commercial paper programs that provide the financing, plus an applicable margin determined by our credit rating.

The estimated weighted average annual interest rate on our indebtedness was approximately 5.9% and 5.8% for the quarters ended April 1, 2006 and March 26, 2005, respectively. Several factors could change the weighted average annual interest rate, including but not limited to a change in reference rates used under our credit facilities and swap agreements.

Our senior unsecured credit facility, senior notes and accounts receivable financing facility contain covenants, including, among other items, minimum interest coverage, maximum leverage ratios, as well as restrictions on dividends, share repurchases, and asset sales and liens. We were in compliance with all financial covenants at April 1, 2006.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki